New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
05:19 EDTLGND, TGTXLigand signs license agreement with TG Therapeutics for IRAK-4
Ligand Pharmaceuticals (LGND) announced the signing of a license agreement with TG Therapeutics (TGTX) for the development and commercialization of Ligandís Interleukin-1 Receptor Associated Kinase-4 inhibitors. The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases. Under the terms of the agreement, Ligand is entitled to receive 125,000 shares of TG Therapeutics common stock, valued at approximately $1M at date of signing, and is eligible to receive $207M in potential milestone payments. Ligand is also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.
News For LGND;TGTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
08:37 EDTTGTXTG Therapeutics enters into global collaboration with Checkpoint Therapeutics
TG Therapeutics (TGTX) announced an agreement with Checkpoint Therapeutics, a newly formed subsidiary of Coronado Biosciences (CNDO), to develop and commercialize Checkpoint's fully human anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. Checkpoint will develop and commercialize these antibodies in solid tumors. The antibodies were generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a Professor in the Department of Cancer Immunology and AIDs at Dana-Farber Cancer Institute. Both programs are currently in pre-clinical development and are anticipated to enter the clinic in 2016. Under the terms of the agreement, TG Therapeutics will make an up-front payment as well as make development and sales-based milestone payments and will pay a tiered single digit royalty on net sales.
08:36 EDTTGTXCoronado forms new subsidiary to develop novel immuno-oncology antibodies
Subscribe for More Information
March 3, 2015
10:01 EDTLGNDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Bacterin (BONE) initiated with a Buy at H.C. Wainwright... Cognizant (CTSH) initiated with a Buy at Argus... Comerica (CMA) initiated with a Neutral at UBS... Delphi Automotive (DLPH) initiated with a Neutral at Northcoast... Dunkin' Brands (DNKN) initiated with a Neutral at UBS... Easterly Government Properties (DEA) initiated with an Outperform at RBC Capital... Fifth Third (FITB) initiated with a Buy at UBS... Hilton (HLT) initiated with an Outperform at RBC Capital... KeyCorp (KEY) initiated with a Neutral at UBS... Ligand (LGND) initiated with a Buy at CRT Capital... M&T Bank (MTB) initiated with a Neutral at UBS... MPLX (MPLX) initiated with a Hold at Evercore ISI... Marriott (MAR) initiated with an Outperform at RBC Capital... Nexvet Biopharma (NVET) initiated with an Outperform at JMP Securities... Regions Financial (RF) initiated with a Neutral at UBS... Shell Midstream (SHLX) initiated with a Buy at Evercore ISI... Starwood (HOT) initiated with a Sector Perform at RBC Capital... Sunoco Logistics (SXL) initiated with a Hold at Evercore ISI... Syneron Medical (ELOS) initiated with a Buy at Brean Capital... Tesoro Logistics (TLLP) initiated with a Buy at Evercore ISI... Valero Energy Partners (VLP) initiated with a Buy at Evercore ISI... Vista Outdoor (VSTO) initiated with a Buy at CRT Capital... Zions Bancorp (ZION) initiated with a Sell at UBS.
08:23 EDTLGNDLigand initiated with a Buy at CRT Capital
Target $102.
March 2, 2015
09:19 EDTLGNDLigand data should establish superiority of Kyprolis, says Roth Capital
Subscribe for More Information
February 19, 2015
14:52 EDTLGNDLigand management to meet with Craig-Hallum
Meetings to be held in Minneapolis on February 23 and in Chicago on February 24 hosted by Craig-Hallum.
09:05 EDTTGTXTG Therapeutics management to meet with Brean Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use